BioCardia (BCDA) to Announce Quarterly Earnings on Monday

BioCardia (NASDAQ:BCDA) will likely be posting its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect BioCardia to announce earnings of ($0.19) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). On average, analysts expect BioCardia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Price Performance

NASDAQ BCDA traded up $0.03 on Monday, hitting $0.86. 6,108 shares of the stock were exchanged, compared to its average volume of 1,374,700. The company’s 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.11. The company has a market capitalization of $9.75 million, a price-to-earnings ratio of -0.94 and a beta of 0.44. BioCardia has a 52-week low of $0.75 and a 52-week high of $2.29.

Analysts Set New Price Targets

BCDA has been the topic of a number of research reports. Wall Street Zen upgraded BioCardia to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research note on Tuesday, June 9th. Finally, Zacks Research downgraded BioCardia from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, BioCardia presently has a consensus rating of “Reduce” and an average price target of $25.00.

Insider Activity at BioCardia

In other news, Director Simon H. Stertzer acquired 39,000 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $39,000.00. Following the completion of the transaction, the director owned 166,338 shares in the company, valued at approximately $166,338. This trade represents a 30.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders purchased 145,900 shares of company stock valued at $137,212. 17.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. DRW Securities LLC bought a new stake in BioCardia during the 4th quarter worth approximately $72,000. Geode Capital Management LLC boosted its holdings in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after buying an additional 27,263 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new position in BioCardia during the second quarter valued at approximately $40,000. 20.57% of the stock is owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.